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Previous studies have shown that miR-203 acts as a tumor-suppressive microRNA in various can-
cers, but its roles in laryngeal carcinoma are still contradicted. Here, we found that miR-203 inhib-
ited the growth of laryngeal cancer cells and survivin was a direct target of miR-203. Moreover,
silencing of survivin recapitulated the effect of miR-203 on cell cycle progression, whereas overex-
pression of survivin reversed this effect. Additionally, qRT-PCR showed the reciprocal relationship
between miR-203 and survivin in laryngeal cancer tissues. These ﬁndings indicate that miR-203
inhibits the proliferation of laryngeal carcinoma cells by directly targeting survivin, suggesting its
application in anti-cancer therapeutics.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of small single-stranded non-
coding RNAs consisting of 20–25 ribonucleotides [1]. After their
initial transcription by RNA polymerase II to generate hairpin
RNA structures, microRNAs undergo sequential processing by the
two RNAse III molecules, Dicer and Drosha, to yield mature miR-
NAs [2–4]. MicroRNAs bind to the 30-untranslated region (UTR) of
their target messenger RNAs via complete or partial base-pair com-
plementarity, which leads to mRNA degradation or translational
repression, respectively [5–7]. Aberrant expression of miRNAs
has been demonstrated to play a critical role in the initiation and
progression of various cancers [8]. A large number of microRNAs
which are aberrantly expressed in cancer tissues have been func-
tionally identiﬁed as tumor-suppressive microRNAs or oncomirs
using gain-of-function and loss-of-function experiments [9,10].chemical Societies. Published by E
f Cancer Biology, Department
y Medical University, 710032
ng), ruizhang@fmmu.edu.cnFull understanding of the biological functions and molecular mech-
anisms of miRNA-mediated processes may provide signiﬁcant ad-
vances in the diagnosis and treatment of malignant disease.
Laryngeal carcinoma is one of the most common head and neck
cancers. Early-stage laryngeal cancer is often curable with surgery
or radiotherapy. However, the outcome for most patients with ad-
vanced disease has not improved dramatically in the last 20 years,
despite therapeutic advances [11]. Characterization of the mecha-
nisms involved in the initiation and progression of laryngeal carci-
noma are important in order to improve the prognosis and
treatment options for patientswith this disease [12]. The expression
patterns and biological functions of microRNAs in laryngeal carci-
noma have been investigated in recent years [13]. For example, let-
7a and miR-34c are downregulated in laryngeal carcinoma and act
as tumor suppressors by directly targeting oncogenes, such as Ras,
c-myc and c-met [14,15]. In contrast, miR-21 functions as an oncomir
by negatively regulating the expression of BTG2, resulting in the in-
creased proliferationof laryngeal cancer cells in vitro and in vivo [16].
In the present study, we designed a gain-of-function experiment
to investigate the role of miR-203 in laryngeal carcinoma cells. We
used a lentivirus-mediated delivery system to stably transfect
Hep-2 laryngeal carcinoma cells with a miR-203 precursor. The
overexpression of miR-203 suppressed the proliferation and colonylsevier B.V. All rights reserved.
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Using combinational analysis of the data from threemicroRNA target
prediction tools, the KEGG pathway database and biological experi-
ments, we demonstrated that survivin is a direct target of miR-203
in laryngeal cancer cells. The functional link between mir-203 and
survivin was further validated by identifying a negative correlation
between the expression levels of miR-203 and survivin mRNA in hu-
man laryngeal cancer tissues using qRT-PCR. Moreover, loss-of-func-
tion and rescue experiments conﬁrmed that survivin plays a critical
role in miR-203-induced G1 phase cell cycle arrest. Collectively, this
study indicates that miR-203 exerts a tumor-suppressive effect dur-
ing laryngeal carcinogenesis via suppressing the expression of survi-
vin.MiR-203 has potential as a target for gene therapy applications in
the treatment of laryngeal cancer.
2. Materials and methods
2.1. Laryngeal tissue specimen collection
Forty laryngeal carcinoma tissues were obtained from Tangdu
Hospital, which is afﬁliated to the Fourth Military MedicalFig. 1. Lentivirus-mediated expression of miR-203 inhibits the proliferation and colon
expression in Hep-2 laryngeal carcinoma cells infected with Lv-Luc or Lv-miR-203 (⁄⁄P <
miR-203, respectively; values are mean ± S.D. of six wells (⁄P < 0.05). (C and D) Quant
carcinoma cells using the colony formation assay. The cell foci were detected using cry
overexpression on the cell cycle in laryngeal carcinoma cells. Hep-2 cells infected with Lv
in media containing 10% fetal bovine serum for 16 h and the cell cycle distribution was
shown in the left panel (E) and the statistical analysis is shown in the right panel (F).University, Xi’an, China. The tissues were frozen in liquid nitrogen
immediately after surgical removal and stored at 80 C until use.
All protocols were approved by the Ethics Committee of the Fourth
Military Medical University.
2.2. Plasmid construction and lentivirus packaging
The humanmiR-203 precursor sequence was ampliﬁed by poly-
merase chain reaction (PCR) using the primers 50-GAATTCGGG-
GATCTGGGCGCAGGGGCC-30 and 50-CTCGAGCCGACCTGGAGCGCG
GAGC-30, cloned into the vector pMD-18T (Takara, Dalian, China)
and conﬁrmed by DNA sequencing. The miR-203 precursor was
then subcloned into the lentivirus-based expression plasmid pLen-
ti-6.3 (Invitrogen) and virus packaging and infection were per-
formed according to standard protocols as recommended by the
manufacturer. The 30-UTR of survivin was ampliﬁed using the
primers 50-GAATTCGGCTGGGCTGCTGCAGGCCGTG-30 and 50-GAT-
ATCGTCTGAAGTGCATTTTCAGTTG-30, cloned into the vector
pMD-18T, conﬁrmed by DNA sequencing and then subcloned into
the pGL3 control vector (Promega, Madison, WI) which had
been modiﬁed as previously described [38] to generate they formation ability of laryngeal carcinoma cells. (A) qRT-PCR analysis of miR-203
0.01). (B) MTT assay of cell proliferation in Hep-2 cells infected with Lv-Luc or LV-
iﬁcation of the effect miR-203 overexpression on the growth of Hep-2 laryngeal
stal violet staining; ⁄⁄P < 0.01 relative to the control group. (E) Impact of miR-203
-Luc and Lv-miR-203 were cultured in serum-free media for 24 h, and then cultured
analyzed by ﬂow cytometry. The percentage of cells in the G1, S and G2 phases is
806 K. Bian et al. / FEBS Letters 586 (2012) 804–809WT-Sur-UTR vector. The PCR productswith the appropriate primers
generated inserts with point substitutions in the miRNA comple-
mentary sites to generate the Mut-Sur-UTR vector. All wild-type
fragment cloning procedures and the generation of point mutations
were conﬁrmed by DNA sequencing.
2.3. Quantitative real-time PCR analysis of mature miR-203 and
survivin mRNA expression
Total RNA was extracted using TRIzol reagent (Invitrogen)
according to manufacturer’s instructions. For miR-203 quantitative
real-time PCR, total RNA was reverse-transcribed with a miRNA-
speciﬁc primer using the miScript Reverse Transcription Kit
(Qiagen, Hilden, Germany) and then quantitative RT-PCR was per-
formed using a miRNA-speciﬁc primer on the ABI PRISM 7500
Real-Time PCR system (Applied Biosciences, Benicia, CA, USA),
using U6 as a normalization control. Quantitative RT-PCR for survi-
vin and the normalization control gene GAPDH was performed
using primers for survivin (forward 50-AGGACCACCGCATCTCTA-
CAT-30; and reverse 50-AAGTCTGGCTCGTTCTCAGTG-30) and GAPDH
(forward 50-TCACCAGGGCTGCTTTTAAC-30 and reverse 50-GACAAG
CTTCCCGTTCTCAG-30) and the relative expression level was calcu-
lated using the comparative Ct method.
2.4. Cell proliferation and colony formation assays
The MTT cell proliferation and colony formation assays were
performed as previously described [26].
2.5. Luciferase reporter assay
Hep-2 cells were cultured in DMEM containing 10% FBS to 80–
90% conﬂuence in 48-well plates. The cells were co-transfected
with 400 ng WT-Sur-UTR DNA plasmid DNA (ﬁreﬂy luciferase
reporter vector containing the survivin 30-UTR) or Mut-
Sur-UTR DNA (ﬁreﬂy luciferase reporter vector containing theFig. 2. Survivin is a direct target of miR-203 in laryngeal carcinoma cells. (A) Overexpres
blot of endogenous survivin protein expression in Hep-2 cells infected with Lv-Luc or Lv
transcription-PCR analysis of endogenous survivin mRNA expression in Hep-2 cells tran
miR-203-binding sequence in the 30-UTR of survivin mRNA. Mutations were generated i
luciferase activity in Hep-2 cells 48 h after co-transfection with the control Renilla lucifer
either the wild-type or mutant survivin 30-UTR (indicated as WT or MUT on the axis, respe
and expressed relative to the normalized luciferase activity of control cells (⁄P < 0.05).survivin 30-UTR mutant) and 20 ng of the control pRL-TK vector
containing Renilla luciferase (Promega) in a ﬁnal volume of
0.2 ml using Lipofectamine 2000 (Invitrogen). The Fireﬂy and
Renilla luciferase activities were measured consecutively using
Dual Glo Luciferase assays (Promega) 48 h after transfection.
2.6. Western blotting
Western blotting was performed as previously described [26]
using an anti-survivin rabbit polyclonal (SC10811 Santa Cruz Bio-
technology, CA, USA) antibody, anti-b-actin mouse monoclonal
antibody (A5441 Sigma–Aldrich, St. Louis, MO, USA) or anti-
myc-tag mouse monoclonal antibody (2276, Cell Signaling
Technology, Danvers, CA, USA).
2.7. Statistical analysis
All data are expressed as the mean ± S.E.M. of at least three sep-
arate experiments. The differences between groups were analyzed
using two-sided Student’s t-tests; P < 0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Overexpression of miR-203 suppresses the growth and colony
formation ability of laryngeal carcinoma cells
Firstly, we used a lentivirus-mediated delivery system to stably
transfect Hep-2 laryngeal carcinoma cells with a miR-203
precursor. As shown in Fig. 1A, the lentivirus-delivery system
increased the expression of miR-203 by more than 700-fold com-
pared with control lentivirus (Lv-Luc)-infected Hep-2 cells.
The MTT assay was performed to evaluate the effect of miR-203
on the proliferation of laryngeal cancer cells. Ectopic expression of
miR-203 signiﬁcantly reduced the growth of Hep-2 cells comparedsion of miR-203 suppresses endogenous survivin expression in Hep-2 cells. Western
-miR-203; b-actin was used as an internal loading control. (B) Quantitative reverse
sfected with Lv-Luc or Lv-miR-203 (⁄P < 0.05). (C) Schematic representation of the
n the miR-203-binding sequence of the survivin 30-UTR as indicated. D: Analysis of
ase expression construct pRL-TK and a Fireﬂy luciferase reporter plasmid containing
ctively). Fireﬂy luciferase activity in each sample was normalized to Renilla activity,
Fig. 4. Expression of miR-203 and survivin mRNA are negatively correlated in
laryngeal carcinoma. Pearson’s correlation analysis of the relative expression levels
of miR-203 (normalized to U6) and the relative expression levels of survivin mRNA
(normalized to GAPDH) determined using qRT-PCR in 40 human laryngeal carcinoma
tissue samples.
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to determine the long-term impact of miR-203 overexpression on
the proliferation of laryngeal cancer cells. The colony formation
ability of Lv-miR-203-infected cells was signiﬁcantly lower than
control-transfected cells (Fig. 1C and D). Taken together, these data
suggest that miR-203may function as a negative regulator of laryn-
geal cancer cell proliferation.
3.2. Lentivirus-mediated miR-203 expression leads to G1 phase cell
cycle arrest in laryngeal carcinoma cells
Wedid not detect signiﬁcant apoptosis inmiR-203-overexpress-
ing laryngeal cancer cells using Annexin-V staining (data not
shown). Therefore, we proposed that the reduced proliferation of
miR-203-overexpressing laryngeal cancer cells was due to altered
cell cycle regulation. Cell cycle distribution analysis demonstrated
that miR-203-overexpressing Hep-2 cells were blocked in the G1
phase, with a corresponding reduction in the percentage of S and
G2/M phase cells observed (Fig. 1E and F). These results indicated
that overexpression of miR-203 mainly inhibits the growth of
Hep-2 laryngeal carcinoma cells by inducing G1 phase cell cycle ar-
rest, not apoptosis.
3.3. Survivin is a direct target of miR-203 in laryngeal carcinoma cells
To understand how miR-203-overexpression inhibits the prolif-
eration of laryngeal cancer cells further, we searched for potential
miR-203 target genes using bioinformatic miRNA target prediction
tools, including TargetScan, PicTar and miRanda [27], and identi-
ﬁed a large number of miR-203 target genes. To investigate the rel-
evant genes which may directly mediate the growth-inhibitory
effects of miR-203, we selected genes which are involved in cell cy-
cle progression for further analysis. Using the DIANA Lab-based
microRNA pathway analysis tool (http://diana.cslab.ece.ntua.gr/
pathways/) to classify all of the predicted genes functionally, and
a combinational strategy to integrate the analytic data from DIANA
Lab and the KEGG database (http://www.genome.jp/kegg/path-
way/hsa/hsa05200.html, Supplementary Fig. S1), we identiﬁed that
the key cell cycle regulation molecule survivin was a putative miR-
203 target. Therefore, we hypothesized that the critical role ofFig. 3. Survivin plays a critical role in miR-203-induced G1 phase cell cycle arrest in laryn
Hep-2 cancer cells stably transfected with a survivin-targeting shRNA. (B and C) FACS cel
transfected Hep-2 cancer cells. (D) Western blot analysis of adenovirus-mediated survivi
targeting the myc-tag was used to detect expression of exogenous C-terminal myc-ta
overexpressing cells 24 h after infection with Ad-survivin or Ad-EGFP.survivin in early cell cycle entry may explain the ability of miR-
203 to induce cell cycle arrest in laryngeal cancer cells.
To test this hypothesis, we analyzed the expression of survivin
in Lv-Luc-infected and Lv-miR-203-infected Hep-2 cells. Western
blot analysis showed a negative correlation between the levels of
miR-203 and survivin protein expression in Lv-miR-203 stably
transfected cells (Fig. 2A). Furthermore, using qRT-PCR, we ob-
served that the levels of survivin mRNA were obviously decreased
in Lv-miR-203-infected Hep-2 cells, compared to control
Lv-Luc-infected Hep-2 cells (Fig. 2B). These ﬁndings suggested that
miR-203 may regulate the expression of survivin negatively by
disrupting the stability of survivin mRNA.
To conﬁrm whether survivin is a direct target of miR-203, we
investigated the miR-203 binding site in the survivin mRNA 30-
UTR (Fig. 2C). We constructed vectors containing the wild-type or
mutant survivin 30-UTR directly fused downstream of a Fireﬂy lucif-
erase gene as previously described [38]. The vectors were transfec-
ted into Lv-Luc-infected and Lv-miR-203-infected Hep-2 cells, and
the transfection efﬁcacy was normalized using a co-transfected
Renilla reporter gene. As shown in Fig. 2D, overexpression ofgeal carcinoma cells. (A) Western blot analysis of endogenous survivin expression in
l cycle distribution analysis of survivin-shRNA-transfected and control EGFP-shRNA-
n expression in Hep-2 miR-203-overexpressing cancer cells. A monoclonal antibody
gged survivin. (E and F) FACS cell cycle distribution analysis of Hep-2 miR-203-
808 K. Bian et al. / FEBS Letters 586 (2012) 804–809miR-203 signiﬁcantly decreased the relative luciferase activity of
the wild-type survivin 30-UTR, but had minimal effects on the rela-
tive luciferase activity of the mutated survivin 30-UTR, indicating
that miR-203 can bind directly to the survivin 30-UTR. Taken to-
gether, these results indicate that survivin is a direct target of
miR-203 in laryngeal cancer cells.
3.4. Knockdown of survivin recapitulates the growth-inhibitory effects
of miR-203 on cell cycle progression in laryngeal cancer cells
Previous studies have indicated that the overexpression of sur-
vivin correlates closely with a poor survival rate and recurrence in
laryngeal cancer; however, the mechanism of this effect has not
been well characterized [36,37]. As shown in Fig. 3A, we estab-
lished stable cell clones that expressed low levels of survivin using
a previously reported survivin-speciﬁc RNAi method [26]. Cell
cycle distribution analysis indicated that knockdown of survivin
blocked the G1/S transition; retaining Hep-2 cells in the G1 phase
(Fig. 3B and C). This was consistent with the effects of infecting
Hep-2 cells with Lv-miR-203 to overexpress miR-203, which fur-
ther conﬁrmed that the downregulation of survivin is essential
for miR-203-induced cell cycle arrest.
3.5. Overexpression of survivin rescues miR-203-induced cell cycle
arrest in laryngeal cancer cells
If survivin is a functional target of miR-203 in laryngeal cancer
cells, then the reintroduction of survivin into cells which express
high levels of miR-203 should antagonize the impact of miR-203
on cell cycle progression. To test this hypothesis, we transfected
exogenous survivin into Lv-miR-203-infected cancer cells using a
previously described adenovirus delivery system [30]. As shown
in Fig. 3D, the expression of survivin in mir-203 overexpressing
cells signiﬁcantly increased after adenovirus-mediated delivery of
survivin. Ectopic overexpression of survivin signiﬁcantly counter-
acted the G1 arrest induced by miR-203 in Hep-2 cancer cells
(Fig. 3E and F). Taken together, the results of this rescue
experiment indicate that reintroduction of survivin abrogates
miR-203–induced cell cycle arrest, suggesting that survivin is a
functional mediator of miR-203 in laryngeal carcinoma cells.
3.6. Expression of endogenous miR-203 inversely correlates with
expression of survivin mRNA in laryngeal carcinoma
It has previously been reported that survivin is frequently over-
expressed in several types of cancer, including laryngeal carcinoma
[36,37]. In light of our observation that overexpression of miR-203
lead to the downregulation of survivin mRNA in Hep-2 cells, it was
logical to postulate that the expression of miR-203 may correlate
inversely with survivin mRNA expression in laryngeal carcinoma
tissues. To validate this hypothesis, the survivin mRNA and mature
miR-203 expression levels were analyzed in forty human laryngeal
cancer tissues using qRT-PCR. As shown in Fig. 4, the expression
levels of endogenous miR-203 negatively correlated with the
expression levels of survivin mRNA (Pearson’s correlation coefﬁ-
cient = 0.1162; P = 0.0314). This data provides further evidence of
a functional link between miR-203 and survivin in laryngeal
cancer.4. Discussion
Although the function and mechanism of numerous microRNAs
have been well characterized in various tumor types, there is evi-
dence to suggest that some tumor-suppressive microRNAs may
serve as oncomirs. For example, miR-203 has been validated as atumor suppressor in hematological malignancies, hepatocellular,
esophageal, bladder, colorectal, gastric and prostate cancer, as a re-
sult of its ability to directly target oncogenes such as DNp63, AKT2,
Src, Runx2, Bcl-wl and ABL1 [17–24]. However, the overexpression
of miR-203 was recently described as a novel biomarker of poor
prognosis in pancreatic adenocarcinoma [25]. Therefore, it is
essential to fully assess the biological function and molecular
mechanism of action of cancer-related microRNAs in each individ-
ual tumor type.
MiR-203 exerts a tumor-suppressive role in many types of can-
cer; however, it was recently reported that miR-203 is upregulated
and may therefore function as an oncogene in laryngeal carcinoma
[16]. As the analysis of global microRNA expression patterns using
only three laryngeal cancer samples may not be sufﬁcient to deter-
mine the function of miR-203 [16], it is essential to determine the
effect of miR-203 in laryngeal carcinoma cells that express differ-
ent levels of miR-203. Here, we for the ﬁrst time demonstrate that
miR-203 exerts its inhibitory effect on the growth of laryngeal can-
cer cells by directly targeting survivin.
It is widely accepted that the cell cycle is under the control of a
number of dynamically expressed genes. Survivin is expressed at
high levels during the G2/M phase and has been demonstrated to
play a critical role in cell cycle progression [28]. Survivin can inter-
act with the cell cycle regulator Cdk4, leading to Cdk2/CyclinE acti-
vation and Rb phosphorylation. Ectopic overexpression of survivin
results in an accelerated S phase and resistance to G1 arrest [29].
Conversely, our previous studies indicated that disruption of the
biological function of wild-type survivin using a dominant negative
approach or RNA interference (RNAi) lead to obvious cell cycle
arrest at the G1/S transition [26,30].
Complicated mechanisms are known to contribute to the regu-
lation of survivin. The transcriptional regulation of survivin has
been well-documented [31], and survivin is also subject to protea-
some-mediated degradation [30,32]. However, the effect of post-
transcriptional regulation on the expression of survivin has not
been determined. As microRNA-mediated post-transcriptional reg-
ulation may signiﬁcantly regulate the expression of survivin, we
conﬁrmed that miR-203 was a negative regulator of survivin
expression at the post-transcriptional level. Recent studies from
other groups have also shown that several other microRNAs
including miR-542-3p, miR218 and miR-708 can also directly bind
to the survivin 30-UTR and inhibit its expression in different types
of cancer [33–35], indicating that microRNA-mediated post-tran-
scriptional silencing mechanisms play a critical role in regulating
the expression of survivin in cancer cells.
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